The Endocrinology and Metabolism Research Institute's Journal Club session was held on July 20, 2026, at Iran University of Medical Sciences. In this session, Dr. Sara Bazgiri, a fellow in Endocrinology and Metabolism, reviewed an article from Frontiers in Pharmacology demonstrating that pioglitazone, despite its significant benefits in reducing stroke and cardiovascular events, is associated with a 21% increased risk of fractures, particularly in women and stroke survivors. These findings emphasize the necessity of an individualized therapeutic approach when prescribing this medication.

A two-day training and empowerment workshop for physicians on the diagnosis, treatment, and comprehensive care of patients with type 2 diabetes was held on July 10-11, 2025, at the Endocrinology and Metabolism Research Institute. The workshop, attended by a group of general practitioners and specialists, provided participants with an update on the latest 2025 American Diabetes Association (ADA) treatment guidelines, alongside practical training on comprehensive diabetic patient visits, standard foot examination, and diabetic retinopathy screening at the institute's outpatient clinic. Faculty members emphasized the importance of timely screening for neuropathy, peripheral arterial disease, and retinopathy, as well as novel pharmacological approaches including SGLT2 inhibitors and GLP-1 receptor agonists in reducing cardiovascular and renal event risks.

Results from a multicenter study in Spain involving 41 men with prolactinomas show that 24% of these tumors are aggressive. In patients with aggressive tumors, the prevalence of visual disturbances (60% vs. 13%), TSH deficiency (70% vs. 13%), and ACTH deficiency (50% vs. 7%) was significantly higher. A stronger correlation was also observed between prolactin levels and tumor diameter in aggressive cases. These findings can aid in the early identification of aggressive tumors and inform a more aggressive therapeutic approach.